Invesaro

Stocks Health care RCEL

NASDAQ · Health care

AVITA Medical, Inc. (RCEL)

AVITA Medical, Inc. brought in $75.6M of revenue over the twelve months to June 30, 2026, up 1.0% from a year earlier. It posted a net loss of $43.1M. In fiscal 2025 capital spending exceeded operating cash flow by $32.2M. At June 30, 2026 it held $9.1M in cash against $46.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Watch RCEL in 60 seconds
Price
$11.67
-1.44% on the day · September 28, 2026
52-week range $3.22 to $12.23
Market cap
$360.9M
Revenue (last 12 months)
$75.6M
+1.0% year on year
Net margin
-57.0%

What AVITA Medical, Inc. does

AVITA Medical, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker RCEL.

Revenue and profit by year

Revenue
FY18: $929K $929K FY18FY20: $5.5M $5.5M FY20FY20: $14.3M $14.3M FY20FY21: $29.2M $29.2M FY21FY22: $34.4M $34.4M FY22FY23: $50.1M $50.1M FY23FY24: $64.3M $64.3M FY24FY25: $71.6M $71.6M FY25
Net income
FY18: -$12.7M -$12.7M FY18FY20: -$25.1M -$25.1M FY20FY20: -$42M -$42M FY20FY21: -$26.6M -$26.6M FY21FY22: -$26.7M -$26.7M FY22FY23: -$35.4M -$35.4M FY23FY24: -$61.8M -$61.8M FY24FY25: -$48.6M -$48.6M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$71.6M-$42.5M-$48.6M-$1.74-$32.2M
2024$64.3M-$56.6M-$61.8M-$2.39-$58.1M
2023$50.1M-$42.7M-$35.4M-$1.40-$39.4M
2022$34.4M-$27.5M-$26.7M$1.07-$19.5M
2021$29.2M-$26.5M-$26.6M$1.17-$26.8M
2020$14.3M-$42.7M-$42M$2.07-$23.3M

Full financial statements: income, balance sheet and cash flow

Next report expected around November 5, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 6, 2025. Not a date the company has announced. See the report calendar

Where RCEL ranks in Health care

Revenue$71.6M
#361 of 742 in Health care · Top 49%
Revenue growth+11.5%
#270 of 529 in Health care · Bottom 49%
Net margin-67.8%
#421 of 541 in Health care · Bottom 22%
Free cash flow margin-45.0%
#371 of 488 in Health care · Bottom 24%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What AVITA Medical, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 25, 2026
  2. August 11, 2026
  3. August 6, 2026
  4. August 6, 2026
    Quarterly report 10-Q · period to June 30, 2026Revenue rose 18% to $21.7M versus the same quarter last year; diluted EPS -$0.25 versus -$0.38.
  5. August 6, 2026
  6. June 8, 2026
  7. June 8, 2026
  8. June 4, 2026
  9. May 14, 2026
    Quarterly report 10-Q · period to March 31, 2026Revenue rose 4% to $19.3M versus the same quarter last year; diluted EPS -$0.35 versus -$0.53.
  10. May 14, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 24, 2026. Insider transactions on SEC

Insider trades

What the people running AVITA Medical, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
June 12, 2026 O'Toole David DCFO Bought 2,000 $3.97 $7.9K Form 4
June 12, 2026 O'Toole David DCFO Received as pay 2,000 $3.97 $7.9K Form 4
June 9, 2026 Woody Joseph FralinDirector Bought 5,200 $4.00 $20.8K Form 4
June 9, 2026 Woody Joseph FralinDirector Bought 5,000 $4.20 $21K Form 4
June 9, 2026 Woody Joseph FralinDirector Bought 5,000 $4.18 $20.9K Form 4
June 3, 2026 Woody Joseph FralinDirector Bought 5,000 $4.10 $20.5K Form 4
June 3, 2026 Woody Joseph FralinDirector Bought 5,000 $4.09 $20.4K Form 4
June 2, 2026 Woody Joseph FralinDirector Bought 5,000 $4.18 $20.9K Form 4
June 2, 2026 Woody Joseph FralinDirector Bought 5,000 $4.21 $21K Form 4
June 1, 2026 Woody Joseph FralinDirector Bought 5,000 $4.34 $21.7K Form 4
June 1, 2026 Woody Joseph FralinDirector Bought 5,000 $4.26 $21.3K Form 4
May 29, 2026 Vance Cary GuyPresident and CEO, Director Received as pay 5,000 $3.05 $15.3K Form 4
May 29, 2026 O'Toole David DCFO Received as pay 5,000 $3.05 $15.3K Form 4
May 20, 2026 O'Toole David DCFO Bought 2,000 $4.26 $8.5K Form 4
May 19, 2026 O'Toole David DCFO Bought 2,000 $4.24 $8.5K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns RCEL

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: The Vanguard Group 4.73% (January 30, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

9 insiders reported holding 761,921 shares in total, about $8.9M at the last price.

HolderSharesAs of
O'Toole David DCFO 152,927 June 12, 2026
McNamara RobertDirector 108,985 January 20, 2026
Woody Joseph FralinDirector 107,961 June 9, 2026
Kelsey NicoleChief Legal Officer 98,390 February 18, 2026
Reed Jan SternDirector 73,225 January 20, 2026
Crowe SuzanneDirector 69,148 January 20, 2026
Cook Jeremy CurnockDirector 62,050 January 20, 2026
Tarnoff Michael EDirector 48,464 January 20, 2026
Vance Cary GuyPresident and CEO, Director 40,771 May 29, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about RCEL

What does AVITA Medical, Inc. do?

AVITA Medical, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker RCEL.

Is AVITA Medical, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $43.1M on revenue of $75.6M.

How much revenue does AVITA Medical, Inc. make?

Over the twelve months to June 30, 2026 AVITA Medical, Inc. reported revenue of $75.6M. That is 1.0% more than a year earlier.

When did AVITA Medical, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the employee stock plan registration from August 25, 2026.

Similar companies

Compare RCEL with

Compare RCEL with any company

Follow RCEL

Get an email when AVITA Medical, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow RCEL: get an email when it files

Where the numbers come from

Financial figures are the values AVITA Medical, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.